# | Category | Status | Study |
1 | C DIFF | Currently Enrolling | SMT19969/C004 A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of Ridinalazole for 10 days with Vancomycin for 10 days in the treatment of Clostridium difficile (C Diff) Infection Major Inclusion/Exclusion Criteria
|
2 | COVID-19 | Currently Enrolling | GS-US-540-5821 Expanded Access Treatment Protocol: Remdesivir for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) Major Inclusion/Exclusion Criteria:
|
3 | HIV | Currently Enrolling | TMB-365-101 Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants Major Inclusion/Exclusion Criteria:
|
4 | HIV | Currently Enrolling | TMC114FD2HTX4004 D/C/F/TAF FDC Evaluated as a Fixed Dose Combination Regimen in Participants Switching from an Integrase Inhibitor who have Experienced Rapid Weight Gain Major Inclusion/Exclusion Criteria:
|
5 | HIV | Currently Enrolling | M19-939 A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With HIV-1 Major Inclusion/Exclusion Criteria:
|
6 | HIV | Currently Enrolling | GS-US-200-4625 A Phase 2/3 Study to Evaluate the Safety and Efficacy of GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced Subjects with HIV-1 Infection. Major Inclusion/Exclusion Criteria:
|
7 | HIV | Currently Enrolling | GS-US-200-4334 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV Major Inclusion/Exclusion Criteria:
|
8 | HIV | Currently Enrolling | MK8591A-020 Randomized, Double-blind, Efficacy, and Safety Study of Doravirine/Islatravir (DOR/ISL) in Treatment-naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection Major Inclusion/Exclusion Criteria:
|
9 | HIV | Currently Enrolling | GS-US-380-5310 Pharmacokinetic, Safety, and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters Major Inclusion/Exclusion Criteria:
|
10 | HIV | Currently Enrolling | GS-US-380-4458 A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Biktarvy versus Tivicay and Descovy in Treatment Naive, HIV-1 and Hepatits B CoInfected Adults Major Inclusion/Exclusion Criteria
|
11 | HSV | Currently Enrolling | AIC316-03-II-01 A randomized, open label, multi-center, comparative trial, to assess the efficacy and safety of Pritelivir versus Foscarnet for the treatment of Acyclovir-resistant mucocutaneous HSV infections in immunocompromised adults Major Inclusion/Exclusion Criteria
|
Currently Enrollingjsukhram2020-05-19T19:25:41+00:00